© 2023 MJH Life Sciences™ and Infection Control Today. All rights reserved.
Scientists at Whitehead Institute have found that small regions within prion proteins are responsible for their infectious properties. Moreover, these regions regulate the ability of prions to cross species barriers. Prions are highly robust and infectious proteins, most notable for their central role in bovine spongiform encephalopathy, commonly called mad cow disease. But very little is known about how prions form aggregates of malformed proteins that ultimately result in disease. This study provides initial insights into how prions recruit and distort healthy neighboring proteins.
Researchers have known for decades that certain neurodegenerative diseases, such as mad cow disease or its human equivalent, Cruetzfeldt-Jakob disease, result from a kind of infectious protein called a prion. Remarkably, in recent years researchers also have discovered non-pathogenic prions that play beneficial roles in biology, and prions even may act as essential elements in learning and memory.
But although prions have received a great deal of scrutiny, scientists still dont understand many of the most fundamental mechanisms of how prions form, replicate and cross from one species to another.
Now, through studying non-toxic yeast prions, scientists at Whitehead Institute have discovered small but critical regions within prions that determine much of their behavior.
These findings provide a new framework for us to begin exploring properties of prion biology that, up until now, have proven difficult to investigate, says Whitehead member and MIT professor of biology Susan Lindquist, senior author on the paper, which will appear in the May 9 online issue of Nature.
Proteins are the cells workhorses, and they need to fold into complex and precise shapes to do their jobs. Prions are proteins that start out normally, but then at some point misfoldrather like an origami swan that comes out looking and acting instead like a vulture.
But prions have another characteristic that enables them to wreak havoc. They recruit other, properly folded proteins into misforming along with them, a process Lindquist calls a conformational cascade. In many organisms, this conformational cascade creates long fibers called amyloids. (The brains of animals that have died from prion infections are literally packed with amyloid clumps.)
In order to glean insights into the mechanics that enable amyloid formation, Peter Tessier, a postdoctoral scientist in Lindquists lab, used peptide arraysglass slides covered with thousands of tiny protein fragments. Traditionally, these arrays are used for finding binding sites within well-behaved proteins. Here, Tessier designed the arrays so that he could observe protein folding and amyloid formation in real time.
Tessier covered the array with peptides from bakers yeast and then added prion protein to the array, also from the same yeast species. He found that a small cluster of peptides recruited the prion proteins to misfold into an amyloid structure. This region of the protein, which Tessier called a recognition element, constitutes about 10 percent of the prion. Tessier repeated this experiment with peptides and a prion taken from pathogenic fungi. The results were the same.
Both prions also maintained a rigid species barrier. The bakers yeast prion could not recruit peptides from the pathogenic fungi cells, and vice versa.
To further verify these results, Tessier accessed a synthetic yeast prion, one that another research group had assembled from pieces of both the bakers yeast and the pathogenic fungi prion. Earlier studies had shown that this synthetic prion could cross the species barrier but did not identify the mechanism. Tessier found that this synthetic prion contained two recognition elements, one for bakers yeast and one for pathogenic fungi. When the prion was placed with peptide fragments from bakers yeast, the bakers yeast recognition element was activated, and likewise for the pathogenic fungi.
Even more striking, Tessier could activate different recognition elements by manipulating environmental conditions, such as temperature. For example, when he conducted the experiment at 4 degrees Celsius, the bakers yeast recognition element switched on. At 37 degrees Celsius, the pathogenic fungi element was activated. In other words, temperature alone could dictate which yeast species the prion could infect. Additionally, the prions behavior could be altered by subtle alterations in the recognition elements amino acid sequence.
While this prion is a laboratory construct not found in nature, these findings provide researchers with a new way to approach old questions, such as why some prion diseases can jump from one species to another but others cant. Tessier and Lindquist say it is likely that natural prions contain more than one recognition element, and recognition elements can slide into a neighboring region. Many external factors can determine which recognition element is activated, in turn influencing the downstream behavior of the prion.
These findings are remarkable for two reasons, says Lindquist, who is also an investigator for Howard Hughes Medical Institute. For one thing, this is the first time that these peptide arrays have been used to study protein folding. Weve taken this platform to a whole new level. Also, weve seen just one small part of this prion inducing proteins to fold. This is an entirely new concept.
Earlier research from the Lindquist lab, published in Nature in 2005, identified the amino acid regions where prions connect with one another to form amyloids. Those interaction regions turn out to be the same regions Tessier identified as recognition elementsfurther confirmation that these regions are key to prion activity.
Tessier and his colleagues plan to further investigate this process in mammalian prions, such as those responsible for mad cow and Cruetzfeldt-Jakob diseases, as well as in other non-prion proteins that can also form amyloid structures.
This research was supported by an American Cancer Society Postdoctoral Fellowship and grants from the DuPont-MIT Alliance and the National Institutes of Health.
Source: Whitehead Institute for Biomedical Research